Changchun Hi-Tech announced that the holding subsidiary Changchun Jinsai Pharmaceutical Co., Ltd.'s application for the marketing of quintuximab injections was accepted by the State Drug Administration. The drug is a recombinant anti-VEGFR 2-person mouse chimeric monoclonal antibody. It is indicated for use in combination with paclitaxel for patients with advanced gastric or gastroesophageal conjunctive adenocarcinoma who have failed previous first-line treatment. Quintuximab injections can specifically bind VEGFR2 to block the VEGF-VEGFR2 signaling pathway and inhibit tumor angiogenesis, thereby inhibiting tumor cell growth.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.